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Abstract
 
In this study, we show that a single intranasal dose of a plasmid encoding active transforming
 
growth factor 
 
b
 
1 (pCMV-TGF-
 
b
 
1) prevents the development of T helper cell type 1 (Th1)-
mediated experimental colitis induced by the haptenating reagent, 2,4,6-trinitrobenzene sul-
fonic acid (TNBS). In addition, such plasmid administration abrogates TNBS colitis after it has
been established, whereas, in contrast, intraperitoneal administration of rTGF-
 
b
 
1 protein does
not have this effect. Intranasal pCMV-TGF-
 
b
 
1 administration leads to the expression of TGF-
 
b
 
1 mRNA in the intestinal lamina propria and spleen for 2 wk, as well as the appearance of
TGF-
 
b
 
1–producing T cells and macrophages in these tissues, and is not associated with the ap-
pearances of fibrosis. These cells cause marked suppression of interleukin (IL)-12 and interferon
(IFN)-
 
g
 
 production and enhancement of IL-10 production; in addition, they inhibit IL-12 re-
ceptor 
 
b
 
2 (IL-12R
 
b
 
2) chain expression. Coadministration of anti–IL-10 at the time of pCMV-
TGF-
 
b
 
1 administration prevents the enhancement of IL-10 production and reverses the sup-
pression of IL-12 but not IFN-
 
g
 
 secretion. However, anti–IL-10 leads to increased tumor ne-
crosis factor 
 
a
 
 production, especially in established colitis. Taken together, these studies show
that TGF-
 
b
 
1 inhibition of a Th1-mediated colitis is due to: (a) suppression of IL-12 secretion
by IL-10 induction and (b) inhibition of IL-12 signaling via downregulation of IL-12R
 
b
 
2 chain
expression. In addition, TGF-
 
b
 
1 may also have an inhibitory effect on IFN-
 
g
 
 transcription.
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Introduction
 
The recent development of various murine models of in-
testinal inflammation has provided new insights into the
pathogenesis and therapy of the human inflammatory
bowel diseases (1–5). Two such models have been particu-
larly useful in the elucidation of the T cells that are in-
 
volved in both the induction and resolution of experi-
mental colitis. The first is Th1 T cell–mediated colitis
developing in C.B-17 SCID mice after transfer of normal
BALB/c CD45RB
 
high
 
 T cells (6–8), and the second is the
hapten-induced model of colonic inflammation in which
either 2,4,6-trinitrobenzene sulfonic acid (TNBS) or ox-
azolone is delivered intrarectally to SJL/J or BALB/c mice
to induce Th1 or Th2 T cell–mediated colitides, respec-
tively (9–11). Both the “SCID transfer model” and the
Th1 TNBS colitis models are characterized by transmural
inflammation associated with severe weight loss as well as
histopathologic features that mimic some characteristics of
Crohn’s disease (12–14).
 
Studies using these models have established that experi-
mental colitis can be modulated by regulatory cytokines.
Thus, in the SCID transfer model, it has been shown that
 
cotransfer of CD4
 
1
 
 antigen-specific T cells producing high
levels of IL-10 (Tr1 cells) at the time of transfer of
 
CD45RB
 
high
 
 cells can prevent the induction of colitis (15).
In addition, it has been shown that oral administration of
TNP-haptenated colonic protein before the time of in-
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trarectal TNBS administration suppresses the ability of the
latter to induce colitis (16). Such suppression after feeding
was most likely due to oral tolerance induction, which had
been shown to be due to TGF-
 
b
 
1–producing Th3 cells (17,
18). This was consistent with the finding that suppression
was associated with the generation of mucosal T cells pro-
ducing TGF-
 
b
 
, and was abrogated by concomitant ad-
ministration of anti–TGF-
 
b
 
 (16). Taken together, these data
on the regulation of experimental colitides by cytokines
strongly support the concept that there is a reciprocal rela-
tion between IL-12 and IFN-
 
g
 
 and IL-10 and TGF-
 
b 
 
in
Th1 T cell–mediated inflammation, and that the outcome
of the inflammation depends on which of these cytokine
groups dominate in any given mucosal immune response.
One approach to the treatment of mucosal inflammation
based on the above-described antiinflammatory roles of IL-
10/TGF-
 
b
 
 is the administration of naked plasmid DNA
encoding one or the other cytokines via an intranasal route.
This approach is based on previous studies that show that
such administration leads to long-term expression of TGF-
 
b
 
or IL-10 in multiple tissues (19, 20). We therefore deter-
mined the effect of TGF-
 
b
 
–encoding DNA on TNBS
colitis using a plasmid engineered to produce an active
form of TGF-
 
b
 
1 that does not require processing for its ac-
tivity (21–23). We found that intranasal administration of
the TGF-
 
b
 
1 plasmid resulted in expression of TGF-
 
b
 
1 in
mucosal tissues, which both prevent induction of TNBS
colitis and reverse established TNBS colitis. In addition, we
showed that these effects were due at least in part to the ca-
pacity of TGF-
 
b
 
1 to induce high levels of IL-10 secretion,
which in turn inhibits IL-12 and TNF-
 
a
 
 production, as
well as the capacity of TGF-
 
b
 
1 to inhibit IL-12 by down-
regulation of the IL-12R
 
b
 
2 chain.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free, 5–6-wk-old male SJL/J mice
obtained from the National Cancer Institute and maintained in
the National Institute of Allergy and Infectious Diseases animal
holding facilities were used in all studies. Animal use adhered to
National Institutes of Health Laboratory Animal Care Guidelines.
 
Plasmid Preparation.
 
Porcine TGF-
 
b
 
1 cDNA that had muta-
tions at 223Cys
 
®
 
gSer and 225Cys
 
®
 
gSer and that encoding bio-
logical active TGF-
 
b
 
1 was obtained from pPK9a (Dr. P. Kon-
daiah, Indian Institute of Science, India) by digestion with Bg1II
at both 5
 
9
 
 and 3
 
9
 
 TGF-
 
b
 
1 cDNA sites (22). The mutant TGF-
 
b
 
1
cDNA thus obtained was subcloned into the BamHI site of the
pSL1180 superlinker vector (Amersham Pharmacia Biotech),
from which it was excised with EcoRI and EcoRV and ligated
into the EcoRI and SmaI sites of the pCI vector under the con-
trol of CMV promotor (Promega). The vector obtained was des-
ignated pCMV-TGF-
 
b
 
. Using a similar approach, murine IL-10
cDNA (American Type Culture Collection) and 
 
b
 
-galactosidase
cDNA (CLONTECH Laboratories, Inc.) were inserted into the
pCI vector and were designated pCMV-IL-10 and pCMV-GAL,
respectively. A large quantity of purified plasmid was prepared by
two cycles of CsC12 ultracentrifugation followed by extensive
dialysis against TE buffer and two cycles of ethanol precipitation;
the purified plasmid was stored at 
 
2
 
70
 
8
 
C until use.
 
Intranasal Administration of Plasmid DNA.
 
20 
 
m
 
l of PBS con-
taining 100 
 
m
 
g of plasmid DNA was administered intranasally to
mice lightly anesthetized with metophane (methoxylflurance;
Schering-Plough Animal Health). The quality of plasmid DNA
was verified by electrophoresis on 1% agarose gel just before ad-
ministration.
 
Induction of TNBS Colitis.
 
TNBS colitis was induced as de-
scribed previously, with slight modifications. For the study of
prevention of induction of TNBS colitis, plasmid was adminis-
tered by intranasal transfer, and 1 h later, 2.5 mg of TNBS
(Sigma-Aldrich) dissolved in 50% ethanol was administered per
rectum as described previously (9, 16). For the study of treatment
of TNBS colitis, 1.5–2.0 mg of TNBS in 45% ethanol was ad-
ministered per rectum, and 7 d later, mice losing weight continu-
ously and/or showing other clinical features of chronic colitis
were administered plasmid DNA by intranasal transfer. A control
group consisted of mice receiving ethanol without TNBS. The
weight of each mouse was monitored every 24 h, and mice were
killed at the indicated time points for assessment of histologic
findings and cytokine production.
 
Treatment of Mice with Anti–IL-10 mAb or rTGF-
 
b
 
1.
 
In some
experiments, mice with established TNBS colitis were adminis-
tered neutralizing anti–IL-10 mAbs mixture (SCX-1 and SCX-2,
1 mg/mouse; DNAX) (24), rat control IgM (2 mg/mouse) ob-
tained from the National Cancer Institute, or rTGF-
 
b
 
1 (each
mouse was administered 5 
 
m
 
g/d for 3 d; R&D Systems) intra-
peritoneally. Optimal doses of rTGF-
 
b
 
1 were determined by pre-
liminary studies (100 ng–10 
 
m
 
g/mouse).
 
Histologic Assessment of Tissues.
 
Tissues obtained at indicated
time points from mice treated in various ways and control mice
were fixed in 10% buffered formalin phosphate (Sigma-Aldrich).
They were then embedded in paraffin, cut into sections, and
stained with hematoxylin and eosin (H and E).
 
1
 
 Stained colon
sections were examined for evidence of colitis using histologic
criteria described previously (9).
 
DNA-PCR and Reverse Transcription PCR Detection of pCMV-
TGF-
 
b
 
1 in Tissues.
 
Tissue DNA was isolated by DNA isolation
kit (Gentra Systems) and subjected to plasmid DNA-PCR. Tissue
RNA was isolated by standard guanidinium isothiocyanate ex-
traction method followed by the treatment with RQ-1 RNAse-
free DNAse (Promega) and subjected to reverse transcription
(RT)-PCR specific for plasmid TGF-
 
b
 
1 mRNA. Primers used
were 5
 
9
 
 primer (22 mer), 5
 
9
 
-AGAAGTTGGTCGTGAG-
GCACTG-3
 
9 
 
derived from the 5
 
9
 
 sequence of synthesized splic-
ing site upstream of TGF-
 
b
 
1 cDNA, and 3
 
9
 
 primer (22 mer)
5
 
9
 
-GAGCTCCGACGTGTTGAACAG-3
 
9 
 
derived from the se-
quence within the TGF-
 
b
 
1 cDNA in the plasmid. The splice site
facilitated the distinction of the sizes between DNA-PCR and
RT-PCR of pCMV-TGF-
 
b
 
1. For glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), the primer sequences are 5
 
9
 
 primer
(24 mer) 5
 
9
 
-GTCTTCACCACCATGGAGAAGGCT-3
 
9 
 
and 3
 
9
 
primer (23 mer) 5
 
9
 
-CATGCCAGTGAGCTTCCCGTTCA-3
 
9
 
.
PCR was performed by thermal cycler for 30 cycles of 94
 
8
 
C for
45 s, 60
 
8
 
C for 60 s, and 72
 
8
 
C for 90 s, and final extension was
performed at 72
 
8
 
C for 10 min. Amplified products were visual-
ized by 2% agarose gel (25).
 
Confocal Immunofluorescence Studies.
 
Tissues as indicated were
put into OCT compound on dry ice, and 5-
 
m
 
m cryosections
 
1
 
Abbreviations used in this paper:
 
 H and E, hematoxylin and eosin; LP, lam-
ina propria; LPMC, lamina propria mononuclear cell; RT, reverse tran-
scription; SAC, 
 
Staphylococcus aureus
 
 Cowans; STAT4, signal transducer
and activator of transcription 4.  
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were cut at standard procedure (9). Dual immunofluorescence
was performed to determine colocalization of intracellular 
 
b
 
-galac-
tosidase and cell surface markers as follows: (a) sections were fixed
in cold acetone and rehydrated in PBS; (b) sections were exposed
to 5% goat serum and hamster anti-Fc blocking mAb (1:100
dilution; BD PharMingen) in PBS for 20 min to block non-
specific Abs of fluorochrome; (c) samples were treated with rabbit
anti–
 
b
 
-galactosidase Ab (1:1,000 dilution; Chemicon) for 40
min, followed by Texas red–conjugated goat anti–rabbit Ab
(Jackson ImmunoResearch Laboratories) and FITC-conjugated
anti-CD3
 
e
 
 or anti-CD11b (BD PharMingen) for 40 min; and (d)
finally, sections were mounted and analyzed by confocal immu-
nofluorescence using on a Leica TCS-NT/SP confocal microscope
using a 40
 
3
 
 objective, numerical aperture 1.2. Fluorochromes
were excited using an argon laser at 488 nm for FITC and a kryp-
ton laser at 568nm for Texas red. Differential interference con-
trast (DIC) images were collected simultaneously with the fluo-
rescence images using the transmitted light detector. Images were
processed using the Leica TCS-NT/SP software (v1.6.551).
 
Isolation and Culture of Lamina Propria T Cells and Macrophages.
 
Lamina propria (LP) mononuclear cells (LPMCs) were iso-
lated from LPs using a modified technique of Van der Heijden
and Stok (26) as described previously. The resultant LPMCs were
plated on a plastic surface for separation into adherent and nonad-
herent cell populations. Nonadherent cells were further enriched
by negative selection using mouse CD41 T cell purification col-
umns (R&D Systems). The resultant cell populations were shown
by flow cytometry (FACScan™; Becton Dickinson) to contain
.90% CD41 T cells. LP T cells thus obtained were suspended in
complete medium consisting of RPMI 1640 supplemented with
3 mM l-glutamine, 10 mM Hepes buffer, 10 mg/ml gentamycin,
100 U/ml each of penicillin and streptomycin (Amersham Phar-
macia Biotech), 0.05 mM 2-ME, and 10% heat-inactivated FCS
(Amersham Pharmacia Biotech), and were cultured at a concen-
tration of 106 cells/ml in 24-well culture plates (Costar) with or
without stimulation by plate-bound anti-CD3e (clone 145-
2C11; BD PharMingen) precoated at 10 mg/ml anti-CD3e in
carbonate buffer (pH 9.5) overnight at 48C and soluble anti-
CD28 (1 mg/ml, clone 37.51; BD PharMingen) for 48 h. The
adherent cell population (LP macrophage-enriched cells, which
were shown by flow cytometry to contain 70% F4/80-positive
cells and a 25% N418-positive cell population). These cells were
cultured at a concentration of 106 cells/ml and stimulated over-
night (18 h) with IFN-g (1,000 U/ml; R&D Systems) and then
with Staphylococcus aureus Cowans (SAC)at a 1:10,000 dilution
(Pansorbin®; Calbiochem) for an additional 24 h. For measure-
ment of TGF-b1, secreting cells were cultured in serum-free me-
dium supplemented with 1% nutridoma-SP (Roche Molecular
Biochemicals) for 60 h as described previously (11).
Cytokine Assays. Supernatants of cell cultures were collected
and assayed for cytokine content (IFN-g, IL-4, IL-12, TNF-a)
by specific ELISA (mini-kit or duo paired cytokines; Endogen).
TGF-b1 concentration was also determined by ELISA (Max
TGFb1 assay kit; Promega), but in this case after the treatment of
sera- or serum-free supernatants with 1 M HCl, followed by the
NaOH neutralization. Optical densities were measured on an
ELISA reader (MR 5000; Dynatech Labs) at a wavelength of 490
nm as described previously (9, 11, 16).
Flow Cytometric Analysis for the Expression of IL-12Rb2 Chain.
Isolated LP T cells were first treated with hamster anti–IL-12Rb2
chain mAb (HAM 10B9; gift of Dr. R. Ehrhardt, Protein Design
Laboratories, Palo Alto, CA) (27) or hamster IgG control (BD
PharMingen). The cells were then washed and incubated with bi-
otinylated anti–hamster IgG (H1L; Jackson ImmunoResearch
Laboratories) followed by PE-conjugated streptavidin and FITC-
conjugated rat anti-CD4 mAb (BD PharMingen). The analysis
was performed on a Becton Dickinson FACScan™ with
CELLQuest™ II software.
Results
Prevention of Induction of TNBS Colitis by Intranasal Ad-
ministration of pCMV-TGF-b1 Plasmid. In initial studies,
we determined the capacity of a plasmid expressing DNA
encoding an active form of TGF-b (pCMV-TGF-b1 plas-
mid) to prevent induction of TNBS colitis. As reported
earlier, rectal instillation of TNBS (2.5 mg in 50% ethanol)
induces colitis in .95% of SJL/J mice and, as shown in Fig.
1, mice treated in this way manifest a major symptom of
such colitis, a profound and sustained weight loss. In con-
trast, mice undergoing colitis induction and also adminis-
tered a single intranasal dose of pCMV-TGF-b1 plasmid
on day 0 of induction showed a transient loss of weight fol-
lowed after day 3 by rapid weight gain to a weight ap-
proaching that of control mice who had received the
pCMV-TGF-b1 plasmid in the absence of TNBS colitis
induction. This transient loss of weight is similar to that
seen previously and in this study in mice receiving 50%
ethanol alone (9, 16; data not shown). Intranasal adminis-
tration of pCMV-TGF-b1 plasmid did not itself cause
weight loss (Fig. 1), and administration of control plasmid
not containing a TGF-b1 DNA cassette (pCI) did not pre-
vent TNBS colitis–associated weight loss (not shown).
The preventive effect of intranasal pCMV-TGF-b1 plas-
mid administration was confirmed by histologic examina-
Figure 1. Intranasal administration of pCMV-TGF-b1 prevented
TNBS-induced colitis in SJL/J mice. Weight changes (mean 6 SD) of
one experiment representative of three independent experiments is
shown. Each group consists of 10 mice treated intranasally on day 0 with
pCMV-TGF-b1 (100 mg/mouse). Alone, h; pCMV-TGF-b1 (100 mg
intranasally) plus rectal instillation of TNBS (2.5 mg/mouse), s; pCMV-
TGF-b1 (100 mg intranasally) plus rectal instillation of TNBS (2.5 mg)
and anti–IL-10 mAbs (SXC-1 and SXC-2 intraperitoneally 1 mg each/
mouse), n; rectal instillation of TNBS alone (2.5 mg), d.44 Intranasal TGF-b Suppression via IL-12Rb2 and IL-10 in TNBS Colitis
tion of colonic tissue. Thus, as shown in Fig. 2, A and B,
mice administered TNBS per rectum alone exhibited se-
vere colitis marked by transmural leukocyte infiltration, loss
of goblet cells, and severe thickening of the colonic wall
compared with mice administered pCMV-TGF-b1 alone.
In contrast, as shown in Fig. 2 C, mice given TNBS per
rectum plus intranasal pCMV-TGF-b1 manifested normal
colonic histology except for a slight thickening of the sero-
sal connective tissue. Importantly, the mice treated with in-
tranasal pCMV-TGF-b1 alone (Fig. 2 A) or in combina-
tion with TNBS (Fig. 2 C) did not exhibit fibrotic changes
in the colon or in multiple other tissues such as the lung,
liver, spleen, and kidney when examined by H and E stain-
ing at 5, 14, 28, and 56 d after TNBS induction. In addi-
tion, no fibrosis was detected in these tissues when they
were stained with Masson’s trichrome stain, which is spe-
cific for collagen deposition (data not shown).
TGF-b1 in Serum and Tissues after Intranasal Administra-
tion of pCMV-TGF-b1 Plasmid. We next conducted a se-
ries of studies focusing on the mechanism of the preventive
effect of intranasal pCMV-TGF-b1 plasmid administration
on TNBS colitis. In a first study, we determined serum lev-
els of TGF-b1 in tissues and cellular localization of the
plasmid-derived TGF-b1 after intranasal administration of
the plasmid. To study serum levels, we initially determined
serum TGF-b1 titers of the active form of TGF-b1 (as de-
fined by TGF-b1 detected without acid treatment; de-
scribed in Materials and Methods) in the serum of mice ad-
ministered pCMV-TGF-b1 plasmid intranasally 5 d after
instillation of TNBS/ethanol per rectum or ethanol alone
per rectum. We found that the serum level was increased in
both groups (13.2 6 0.4 ng/ml, n 5 5 and 12.2 6 0.3 ng/
ml, n 5 5, respectively) compared with similar mice not
administered intranasal plasmid (3.5 6 0.2 ng/ml, n 5 5
and 3.4 6 0.2 ng/ml, n 5 5, respectively). In contrast, total
TGF-b1 levels in serum (defined as TGF-b1 detectable af-
ter acid treatment; described in Materials and Methods)
were much higher and did not differ among the various
groups tested, i.e., those administered intranasal pCMV-
TGF-b1 plasmid or not administered plasmid (range: 87.9–
109.2 ng/ml).
To study tissue distribution of TGF-b1 DNA and
mRNA after intranasal administration of pCMV-TGF-b1,
we performed PCR and RT-PCR on DNA and mRNA,
respectively, extracted from various tissues. Here, we took
advantage of the fact that the pCMV-TGF-b1 plasmid
possesses a splicing site at the 59 end of the TGF-b1 DNA,
which gave rise to RNA that could be distinguished by
size from both contaminating plasmid TGF-b1 DNA in
RNA extracts that persisted after treatment with DNAse
and endogenous TGF-b1 mRNA. As shown in Fig. 3,
pCMV-TGF-b1 DNA could be detected in the DNA ex-
tracted from lung, spleen, and colons of mice administered
intranasal pCMV-TGF-b1 plasmid at day 5 and 4 wk after
administration of plasmid. However, such DNA could not
be detected 2 mo after such administration (not shown). In
contrast, TGF-b1 mRNA could be detected at day 14 af-
ter administration of plasmid in all tissues, but was not de-
tected in colon and spleen tissues and only faintly in lung
tissue at 28 d.
In further studies to determine if pCMV-TGF-b1 plas-
mid is expressed in T cells and/or macrophages in mice ad-
ministered this plasmid and undergoing induction of TNBS
colitis, we administered to such mice an equivalent (surro-
gate) plasmid in which the TGF-b1 DNA cassette was re-
placed by a b-galactosidase DNA cassette, as b-galactosi-
dase but not TGF-b1 can be reproducibly detected in cells
as a marker for the presence of a plasmid DNA. In these
Figure 2. Histologic analysis of the colon
from SJL/J mice at day 5 after initial intra-
nasal administration of pCMV-TGF-b1 in
the TNBS colitis induction. H and E–stained
cross section of colon (original magnifica-
tion: 3100) from a mouse administrated
(A) pCMV-TGF-b1 (intranasally) alone
showing normal appearance; (B) TNBS
alone showing severe transmural colitis; (C)
pCMV-TGF-b1 and rectal instillation of
TNBS showing normal histology except for
minimal increase in thickness of the colon
wall; and (D) pCMV-TGF-b1 and rectal
instillation of TNBS plus anti–IL-10 mAbs
showing normal histology except for mini-
mal increase in thickness of the colon wall.45 Kitani et al.
studies, we used immunostaining with anti–b-galactosidase
to detect b-galactosidase rather than the X-gal reaction, as
such immunostaining has been shown to be the more sen-
sitive detection method (28, 29). Accordingly, tissues har-
vested from mice 5 d after intranasal administration of
pCMV-GAL and intrarectal administration of TNBS were
stained with FITC-labeled anti-CD3 or anti-CD11b and
Texas red–labeled rabbit anti–b-galactosidase, then were
examined by confocal microscopy to detect cells colocaliz-
ing the cell surface markers with cytoplasmic b-galactosi-
dase. As shown in Fig. 4, A and B, cells in tissues exhibiting
both green cell surface staining (CD31 cells) as well as red
cytoplasmic staining (b-galactosidase–containing cells)
were found in CD41-enriched cell cytospin samples from
spleen and inflamed colon tissues. In addition, as shown in
Fig. 4 C, CD11b1/b-galactosidase colocalizing cells were
also found in inflamed colon tissue. One CD11b1/b-galac-
tosidase1 binucleated cell with arrow could be a granulo-
cyte, as CD11b is also positive in granulocytes. Scanning of
multiple fields showed that CD11b1/b-galactosidase colo-
calizing cells were more numerous than CD31/b-galac-
tosidase colocalizing cells, and both types of cells tended to
occur as focal accumulations. Finally, as shown in Table I,
after administration with pCMV-TGF-b1, the splenic
CD41 T cell–enriched cell population as well as the ad-
herent cell population produced increased the amount of
TGF-b1 in vitro. Taken together, these studies show that
pCMV-TGF-b DNA is taken up by both CD31 T cells
and CD11b1 adherent cells that are present in inflamed tis-
sues of mice administered TNBS.
In additional studies, we also sought insight into means
by which intranasally administered pCMV-TGF-b plasmid
gains access to intestinal tissue. In these studies, we showed
first that intranasally administered plasmid as detected by
PCR is present in gastric contents soon after intranasal ad-
Figure 3. Analysis of pCMV-TGF-b1 DNA and mRNA in tissues by
PCR and RT-PCR, respectively, at 5, 14, and 28 d after intranasal ad-
ministration of pCMV-TGF-b1 and TNBS treatment. RT-PCR detects
spliced mRNA message that differs in size from DNA and is thus not due
to plasmid DNA contamination of endogenous TGF-b1 mRNA (de-
scribed in text). Lane M, marker; lanes 1, 4, and 7, lung; lanes 2, 5, and 8,
colon; lanes 3, 6, and 9, spleen; lanes 1–3, day 5; lanes 4–6, day 14; lanes
7–9, day 28. In TGF-b1 mRNA, a faint band of 726 bp was also detected
because of the presence of unspliced message. One experiment represen-
tative of three independent experiments is shown.
Figure 4. Confocal immunofluorescence
studies indicating that intranasally adminis-
tered CMV-GAL is taken up by CD31 T
cells as well as by CD11b1 cells. Represen-
tative confocal microscopy fields from (A)
cytospin preparation of spleen CD41 cells
(2 3 104 cells per slide) enriched by immuno-
column (original magnification: 31,000)
and (B) and (C) colon sections obtained
from mice with mild TNBS colitis (3400).
Differential interference contrast (phase
contrast) images (top) were collected simul-
taneously with the fluorescence images us-
ing the transmitted light detector. Two-
color immunofluorescence (bottom) was
performed with rabbit anti–b-galactosidase
Ab followed by Texas red–goat anti–rabbit
IgG Ab and FITC–anti-CD3 mAb (A) and
(B) or FITC–anti-CD11b (C). In staining of
cytospin preparation, cells were first stained
with FITC anti-CD3 and fixed with 4%
paraformaldehyde, then were stained with
rabbit anti–b-galactosidase Ab followed by
Texas red–goat anti–rabbit IgG Ab. 9 6 5
cells per slide were CD31 b-galactosidase1
in five cytospin slides.46 Intranasal TGF-b Suppression via IL-12Rb2 and IL-10 in TNBS Colitis
ministration, indicating that one possible mode of access is
inadvertent swallowing of plasmid DNA followed by direct
entry of DNA into LP macrophages and T cells. In addi-
tion, we also observed that intranasal administration of plas-
mid is followed by the appearance of plasmid DNA, again
detected by PCR, in draining cervical lymph nodes but not
in the blood (serum or formed elements) at 24 h (data not
shown). Because it has been shown that cells originating in
cervical nodes can migrate via lymphatics to other mucosal
tissues, lymphatic migration of cells from nasal and/or cer-
vical areas to the gastrointestinal tract is a second possible
mode of access.
Effect of Intranasal Administration of pCMV-TGF-b1 Plas-
mid on Cytokine Production in Mice Undergoing Induction of
TNBS Colitis. In the next series of studies, we deter-
mined the effect of intranasal pCMV-TGF-b1 administra-
tion on cytokine production in mice subjected to induc-
tion of TNBS colitis. In these studies, LPMCs were
obtained from colons of mice 5 d after the induction of
TNBS colitis both treated and not treated with intranasal
pCMV-TGF-b1 plasmid or control plasmid. Then, after
culture with anti-CD3/anti-CD28 (described in Materials
and Methods), TGF-b1, IFN-g, and IL-10 levels were
measured in the culture supernatant.
As shown in Fig. 5, anti-CD3/anti-CD28–stimulated
LPMCs obtained from mice given intrarectal TNBS and
also administered intranasal pCMV-TGF-b1 produced
greatly increased amounts of TGF-b1 compared with cells
obtained from mice induced with TNBS alone. In addi-
tion, similarly stimulated LPMCs from mice administered
intranasal pCMV-TGF-b1 and not given TNBS also pro-
duced increased amounts of TGF-b1, but not to the extent
seen in the TNBS-induced mice. Thus, the data is consis-
tent with the view that T cells expressing the pCMV-
TGF-b1 plasmid are nonspecifically induced to produce
TGF-b1 via the CMV promotor in the context of an in-
flammation. This view is supported by additional studies
that showed that although unstimulated LPMCs and spleen
mononuclear cells obtained from mice induced with in-
trarectal TNBS do not produce significant amounts of
TGF-b1, the same cells stimulated by a variety of poly-
clonal stimulants (anti-CD3/anti-CD28, PMA/ionomycin,
and Con A) produce very substantial amounts of TGF-b1
(data not shown). Finally, it should be noted that these ex
vivo studies are likely to reflect in vivo TGF-b1 produc-
tion because, as noted above, mice administered intranasal
pCMV-TGF-b1 exhibited increased levels of circulating
TGF-b1 in the circulation.
As further shown in Fig. 5, anti-CD3/anti-CD28–stim-
ulated LPMCs from mice given TNBS per rectum that
were administered pCMV-TGF-b1 intranasally also pro-
duced markedly decreased levels of IFN-g. This was in
striking contrast to the LPMCs from mice given TNBS per
rectum and not administered pCMV-TGF-b1 plasmid or
mice administered control plasmid (pCI), which produced
high levels of IFN-g. Taken together, these results suggest
that there is a reciprocal relation between TGF-b and IFN-g
secretion, and that TGF-b secreted by cells expressing the
pCMV-TGF-b1 plasmid suppresses IFN-g secretion.
In parallel studies, we determined the production of IL-
10 in the same anti-CD3/anti-CD28–stimulated LPMC
populations. Thus, as shown in Fig. 5, although TNBS
colitis induction with or without intranasal control plasmid
administration was associated with a moderate rise in IL-10
production, such induction with intranasal administration
of pCMV-TGF-b1 was associated with a striking increase
in IL-10 production. In view of the dramatic effect of
pCMV-TGF-b1 administration on IL-10 production and
thus the possibility that TGF-b was acting through IL-10
to prevent TNBS colitis, we also measured the secretion of
cytokines in mice treated with anti–IL-10 at the time of
TNBS colitis induction (Materials and Methods). As shown
in Fig. 5, although anti–IL-10 administration completely
reversed the stimulatory effect of pCMV-TGF-b1 on IL-
10 secretion, it had no effect on either TGF-b1 production
or IFN-g production. This, plus the fact that anti–IL-10
administration to the whole mouse had no effect on the
ability of pCMV-TGF-b1 to prevent TNBS colitis as
shown by weight change or histologic analysis (Fig. 1 and
Fig. 2 D), strongly suggests that the plasmid is not acting
solely through induction of IL-10 secretion.
The Effect of Intranasal pCMV-TGF-b1 Plasmid Adminis-
tration on IL-12 Production and Signaling during Induction of
TNBS Colitis. Given the effect of intranasal pCMV-TGF-
b1 administration on IFN-g secretion after TNBS colitis
induction, it was logical to determine the effect of such
Table I. TGF-b1 and IL-10 Production of Spleen Cells after 
Intranasal Transfer of pCMV-TGF-b1 Plasmid or Intraperitoneal 
Administration of Recombinant TGF-b1
Cell population TGF-b1 IL-10
(pg/ml) (pg/ml)
None T cells (total) 45 140
Adherent cells 40 124
TGF-1 plasmid* T cells (total) 812 1,238
CD8 T cells 673 1,483
CD4 T cells 935 745
Adherent cells 796 438
rTGF-b1‡ T cells (total) 112 106
CD8 T cells 98 70
CD4 T cells 118 120
Adherent cells 72 597
Cells were obtained from groups of five mice killed on day 4. Adherent
cells were separated by adherence to plastic dishes, and T cells were
separated from nonadherent cells by passing through a T cell column.
CD4-enriched and CD8-enriched T cells were further separated by
magnetic beads after incubation with anti-CD8 or anti-CD4 mAb. T
cells were stimulated in vitro with anti-CD3/anti-CD28, whereas
adherent cells were stimulated with SAC plus IFN-g. TGF-b1 and IL-
10 production was determined by ELISA in duplicate.
*100 mg intranasally on day 0.
‡5 mg/d intraperitoneally for 3 d.47 Kitani et al.
plasmid administration on IL-12 secretion and signaling. In
this case, purified LPMCs obtained from mice 5 d after
TNBS administration were stimulated with SAC and IFN-g
(described in Materials and Methods) rather than anti-
CD3/anti-CD28, and IL-12 p70 was measured in cultured
supernatants. As again shown in Fig. 5, IL-12 secretion was
substantially increased in cultures of cells from mice induced
with TNBS per rectum and either treated or untreated with
control pCI plasmid compared with mice induced with
ethanol alone. In contrast, IL-12 secretion was reduced to
baseline levels in mice induced with TNBS per rectum and
treated with intranasal pCMV-TGF-b1 plasmid. However,
perhaps more importantly, administration of anti–IL-10 at
the time of TNBS colitis induction as described above re-
verses the suppressive effect on IL-12 secretion exerted by
intranasal pCMV-TGF-b1 plasmid administration. This
was especially noteworthy because, as already noted, anti–
IL-10 production did not relieve the suppressive effect of
plasmid administration on IFN-g secretion.
The above results showing that intranasal pCMV-TGF-b
plasmid administration when associated with anti–IL-10
administration gives rise to an increased IL-12 response yet
has no effect on a IFN-g response suggests that TGF-b se-
cretion interferes with IL-12 signaling. To test this possibil-
ity, we determined the expression of the b2 chain of the
IL-12R by flow cytometry using a mAb specific for the b2
chain (27). As shown in Fig. 6, induction of TNBS colitis
followed by isolation of LPMCs at 3 d after induction led
to increased b2 chain expression; in contrast, concomitant
intranasal administration of pCMV-TGF-b1 plasmid at the
time of TNBS induction led to LPMCs that exhibited de-
creased b2 chain expression. These data were corroborated
by in vitro studies in which spleen T cells were isolated
from mice that had undergone TNBS colitis induction and
were then stimulated in vitro with Con A alone or in the
presence of exogenous TGF-b or IL-10. Although TGF-
b1 downregulated b2 chain expression, IL-10 did not (data
not shown). Taken together, these data established that the
production of TGF-b1 by cells in mice given intranasal
pCMV-TGF-b1 plasmid leads to abrogation of the Th1
response (at least in part) by blocking IL-12 signaling.
Effect of Intranasal Administration of pCMV-TGF-b1 Plas-
mid on Established TNBS Colitis. In further studies, we
determined if pCMV-TGF-b1 plasmid administration
could reverse established TNBS colitis in addition to pre-
Figure 5. Cytokine production by LP-
MCs from mice administered intranasal
pCMV-TGF-b1 and control plasmid un-
der various conditions. LPMCs were iso-
lated from pooled colon cell populations (n ^
6) obtained at day 5 after induction of
TNBS colitis and intranasal administration
of pCMV-TGF-b1 or pCI control plasmid,
with or without coadministration of intra-
peritoneal anti–IL-10 mAbs (SXC-1 and
SXC-2). LPMCs were stimulated with anti-
CD3e and anti-CD28 mAb or SAC and
IFN-g as described in Materials and Meth-
ods. All four cytokines in the supernatant
were determined by ELISA in duplicate
wells, and SD was within 5%. Values from
one representative study out of three inde-
pendent experiments with consistent results
are shown. These data are obtained from
the same experiment shown in Fig. 1.
Figure 6. Intranasal administration of pCMV-TGF-b1 to mice with
TNBS colitis decreases the expression of IL-12Rb2 chain expression on
LP CD41 T cells. Mice were administered TNBS on day 0 with or with-
out intranasal administration of pCMV-TGF-b1. LPMCs were isolated at
day 5 and stained with FITC–anti-CD4, streptavidin-PE, and IL-12b2R
mAb (described in Materials and Methods). The flow cytometric profile of
IL-12b2R expresssion after gating CD41 T cell population is shown. One
experiment representative of three independent experiments is shown.48 Intranasal TGF-b Suppression via IL-12Rb2 and IL-10 in TNBS Colitis
venting its development as described above. Accordingly,
SJL/J mice were administered TNBS per rectum to induce
TNBS colitis, and at day 7 after colitis was established, they
were administered a single dose of intranasal pCMV-TGF-
b1 plasmid along with an intraperitoneal injection of anti–
IL-10 or a control rat IgM; alternatively, the mice were ad-
ministered rTGF-b1 (5 mg/d for 3 d). As shown in Fig. 7,
mice treated with pCMV-TGF-b1 plus control rat IgM
manifested a striking reversal of weight loss, accompanied
by an improvement in coat appearance and activity and, as
shown in Fig. 8, A, B, and D, almost complete resolution
of macroscopic and microscopic evidence of colitis (data
not shown). In some contrast, as also shown in Fig. 7, mice
treated with intranasal pCMV-TGF-b1 plus anti–IL-10
had a less dramatic effect on weight gain and, as shown in
Fig. 8 C, only a moderate resolution of macroscopic evi-
dence of colitis. Finally, intraperitoneal administration of
rTGF-b1 had no affect on the course of established TNBS
colitis, i.e., the mice did not recover weight and did not re-
verse colitis at either the microscopic or macroscopic levels
(data not shown). As shown in Table I, the splenic T cell
population exhibited only a small increase in TGF-b1 pro-
duction and no increase in IL-10 production after such ad-
ministration, whereas adherent cells (macrophages) pro-
duced an increased amount of IL-10 but not TGF-b1.
Analysis of Cytokine Production in SJL/J Mice with Estab-
lished TNBS Colitis Treated with pCMV-TGF-b1 with or
without Concomitant Administration of Intraperitoneal Anti–IL-
10. As noted above, concomitant anti–IL-10 administra-
tion does not alter the capacity of pCMV-TGF-b plasmid
given intranasally to prevent TNBS colitis, but it does di-
minish the capacity of the plasmid to treat established
TNBS colitis. To determine the basis of this difference, we
measured cytokine production by stimulated LP cells (in
this case, LP T cells or purified adherent cells) extracted
from mouse colons 5 d after intranasal plasmid and/or in-
traperitneal anti–IL-10 administration. As shown in Fig. 9,
cells from mice treated with pCMV-TGF-b1 plasmid with
and without intraperitoneal anti–IL-10 administration ex-
hibited decreased IFN-g production. Furthermore, as also
shown in Fig. 9, administration of pCMV-TGF-b was
again accompanied by downregulated IFN-g–induced IL-
12 production, and this was again reversed by administra-
tion of anti–IL-10 but not by administration of control rat
IgM. In parallel with the situation obtained during admin-
istration of pCMV-TGF-b1 plasmid to mice during induc-
tion of TNBS colitis, such administration of the plasmid in
established colitis led to increased IL-10 production by LP
T cells (Fig. 9), but had little effect on production of IL-10
by LP adherent cells (data not shown).
Finally, as shown in Fig. 10, intranasal pCMV-TGF-b1
administration plus intraperitoneal anti–IL-10 administra-
tion led to increased adherent cell TNF-a secretion, which
was not seen in the absence of anti–IL-10 administration.
Thus, it appears that the ability of anti–IL-10 administration
to decrease the effect of intranasal pCMV-TGF-b1 plasmid
administration on established TNBS colitis is due to loss of
the downregulating effect of IL-10 on TNF-a secretion.
Discussion
In this study, we explored the therapeutic potential of
intranasal delivery of plasmid DNA encoding active TGF-
b1 (pCMV-TGF-b1) in a murine model of experimental
colitis (TNBS colitis), and showed that the administered
Figure 7. Intranasal administration of pCMV-TGF-b1 abrogates estab-
lished TNBS colitis in SJL/J mice. Weight changes of mice in one exper-
iment (mean 6 SD) representative of three independent experiments is
shown. Each group consisted of 15 mice administrated TNBS (1.5–2.0
mg/mouse) at day 0 and treated with pCMV-TGF-b1 (100 mg/mouse
intranasally) and rat control IgM (2 mg/mouse intraperitoneally) at day 7,
s; pCMV-TGF-b1 and anti-IL-10 mAbs (SXC-1 and SXC-2, 1 mg/
mouse intraperitoneally) at day 7, n; rTGF-b1 (5 mg/mouse intraperito-
neally each day on days 7–9), j; no treatment, d.
Figure 8. Gross appearance of colons from SJL/J mice at 12 d after ad-
ministration of TNBS on day 0, and after treatment with intranasal ad-
ministration of pCMV-TGF-b1 and intraperitoneal administration of
anti–IL-10 mAbs or rat control IgM on day 7. Representative colons
from (A) a normal control mouse, (B) a mouse treated with pCMV-TGF-
b1 (intranasally) and rat control IgM (intraperitoneally), (C) a mouse
treated with pCMV-TGF-b1 (intranasally) and anti–IL-10 mAbs (intra-
peritoneally), and (D) nontreated established colitis.49 Kitani et al.
plasmid was highly effective both in preventing induction
of colitis and in ameliorating established colitis. In discuss-
ing the immunological mechanisms underlying this thera-
peutic effect and how they relate to other models of exper-
imental mucosal inflammation, it is important to emphasize
that most such models of inflammation are Th1 T cell–
driven processes that are highly dependent on the produc-
tion of IL-12 and the activation of the (signal transducer
and activator of transcription 4 (STAT4) signaling pathway
(30, 31). Thus, in the TNBS colitis model, treatment of
mice with anti–IL-12 leads to complete prevention of dis-
ease or resolution of already established disease. In addition,
in the cell transfer model of colitis obtained by the recon-
stitution of Tge26 mice with cells from wild-type mice,
administration of anti–IL-12 prevents colitis, as does recon-
stitution of Tge26 mice with cells from with STAT42/2
cells. Similarly, in the transfer model of colitis obtained
by the reconstitution of recombination activating gene
(RAG)2/2 mice with CD45RBhi cells, although reconsti-
tution with cells from wild-type mice causes severe colitis,
reconstitution with cells from STAT42/2 mice causes only
mild colitis (32). It is also important to emphasize that the
inflammation in these and other models are conditional on
the IL-12/STAT4 pathway but are not conditional on the
induction of IFN-g secretion. This is shown by the fact
that TNBS colitis can be induced in IFN-g2/2 mice, and
reconstitution of Tge26 transgenic mice or RAG2/2 mice
with cells from IFN-g2/2 mice does not prevent the devel-
opment of colitis (32). Thus, it is highly likely that other
cytokines induced by the IL-12/STAT4 pathway, such as
TNF-a, are sufficient to support the development of mu-
cosal inflammation, although further study is required to
determine how IL-12/STAT4 pathway–dependent TNF-a
induction in T cells leads to the abundant TNF-a produc-
tion in non-T cells known to be necessary for colitis (33–
35). Taken together, these considerations support the view
that IL-12 production and/or signaling is a key concomi-
tant of many forms of experimental mucosal inflammation,
and one can therefore predict that the suppressive effect of
a plasmid causing the secretion of TGF-b1 acts by affecting
the production of or signaling by IL-12.
Indeed, this prediction appears to hold true. First, intra-
nasal pCMV-TGF-b plasmid administration suppressed IL-
12 production, probably via the induction of IL-10 secre-
tion, as no suppression was observed when the mice were
coadministered anti–IL-10. Second, intranasal pCMV-
Figure 9. In vitro cytokine production
by LP T cells or by LP adherent macro-
phages from mice with established TNBS
colitis (day 12 after induction). Mice were
treated with intranasal administration of
pCMV-TGF-b1 or pCI control plasmid
and intraperitoneal administration of anti–
IL-10 mAbs or rat control IgM on day 7.
LPMCs were isolated from pooled colon
cell population (n ^ 6), then separated into
LP T cells and macrophages. LP T cells
were stimulated with anti-CD3e/anti-
CD28 mAb for TGF-b1, IFN-g, and IL-10
production, and LP macrophages were
stimulated with SAC and IFN-g for IL-12
production. All four cytokines in the super-
natant were determined by ELISA in dupli-
cate wells, and SD was within 5%. One ex-
periment representative of three is shown;
these data are obtained from the same ex-
periment shown in Fig. 7.
Figure 10. In vitro TNF-a production by LP macrophages obtained
from mice treated with intranasal administration of pCMV-TGF-b1 and
coadministration intraperitoneally of anti–IL-10 mAbs or rat control IgM.
Cells were obtained at day 5 during the induction phase (hatched bars) or
at day 12 during the established phase (black bars) of TNBS colitis, and
were cultured with SAC and IFN-g for 24 h. Results of one representa-
tive experiment of three are shown. ELISA was performed in duplicate
wells, and SD was within 5%.50 Intranasal TGF-b Suppression via IL-12Rb2 and IL-10 in TNBS Colitis
TGF-b plasmid administration inhibited IL-12 signaling, as
shown by the fact that although administration of the plas-
mid along with coadministration of anti-IL-10 negated the
effect of the plasmid on IL-12 production, IFN-g secretion
remained low. In addition, plasmid administration was as-
sociated with downregulation in the capacity of T cells to
express the b2 chain of the IL-12 receptor, which expres-
sion is critical for Th1 differentiation (27, 36, 37). On these
bases, we postulate that the ability of intranasal pCMV-
TGF-b plasmid administration to protect and/or treat
TNBS colitis and, by extension, other Th1 colitides, is due
to its indirect effect on IL-12 production via IL-10 produc-
tion and its direct effect on IL-12 induction and IFN-g se-
cretion. The latter, in turn, occur via downregulation of
IL-12Rb2 chain expression or through an as yet poorly
understood effect of TGF-b on IFN-g transcription. In
any case, the end result is that plasmid administration acts
through IL-12 to inhibit secretion of any of a variety of
downstream inflammatory cytokines.
Previous studies of experimental murine colitis have pro-
vided evidence that both TGF-b and IL-10 play counter-
regulatory roles in the Th1 pathway, leading to inflamma-
tion. With regard to TGF-b, it has been shown that TNBS
colitis can be prevented by feeding TNP-haptenated co-
lonic protein before the time of TNBS administration per
rectum (16). Moreover, such prevention is accompanied by
the appearance of TGF-b–producing T cells and is abro-
gated by administration of anti–TGF-b. Recently we have
shown that in this setting TGF-b is produced by TGF-b–
producing CD41 T cells which, when transferred to naive
recipients, prevent induction of TNBS colitis or colitis
induced by concomitantly transferred IFN-g–producing
CD41 T cells (our unpublished results). Similarly, in the
SCID transfer model, it has been shown that coadministra-
tion of anti–TGF-b prevents the ability of CD45RBlo T
cells to prevent colitis induced by CD45RBhi T cells (8, 38,
39). The above data relating to the suppressive effect of
TGF-b are paralleled by evidence relating to the suppres-
sive effect of IL-10. Thus, it has been shown that
CD45RBlo T cells from IL-102/2 mice fail to protect
SCID mice given CD45RBhi T cells from the develop-
ment of colitis and, more importantly, administration of Ab
to IL-10R also prevents the ability of CD45RBlo T cells to
protect SCID mice from the development of colitis (40).
The above studies showing counterregulatory effects of
both TGF-b and IL-10 secretion on the development of
colitis do not necessarily imply that the effects of these cy-
tokines are independent. On the contrary, it is possible that
IL-10 is necessary for the development of TGF-b T cells or
for TGF-b secretion; conversely, it is possible that TGF-b
is necessary for development of IL-10–secreting T cells or
IL-10 secretion.
The present data relate to this question because they
show that in a situation where TGF-b production is due to
the presence of a CMV promotor–driven plasmid, and thus
is IL-10 independent, TGF-b does not require IL-10 to
bring about suppression. In other words, TGF-b is a suffi-
cient suppressor effector molecule. However, it remains
possible that in normal mice development of TGF-b–pro-
ducing T cells and/or TGF-b secretion is dependent on
IL-10. In addition, it remains possible that in normal mice
TGF-b secretion acts in part via IL-10, as we show in this
study that TGF-b induces IL-10 secretion, and it is known
that IL-10 inhibits IL-12 secretion (41). One last point
concerning the effect of intranasal administration of a TGF-
b1–encoding DNA on IL-10 production is that such ad-
ministration leads to IL-10 production in both T cells and
macrophages. In contrast, in both an earlier study and this
study, it was shown that administration of rTGF-b1 in-
duced IL-10 production by macrophages, but not T cells
(42). This difference may explain the fact that administra-
tion of rTGF-b1 did not affect established TNBS colitis, as
the suppressive effect of TGF-b1 may be dependent on T
cell secretion of IL-10.
One caveat to the above sufficiency of TGF-b as a sup-
pressor effector is that the effect of anti–IL-10 on the ability
of pCMV-TGF-b plasmid to affect TNBS colitis depended
somewhat on whether the anti–IL-10 was administered
during induction of colitis or after colitis was established.
Thus, although plasmid administration completely blocked
the induction of colitis in the presence of anti–IL-10 ad-
ministration, it only partially reversed established colitis un-
der these circumstances. This partial effect of anti–IL-10 in
established colitis cannot be ascribed to an incomplete abil-
ity of anti–IL-10 to neutralize IL-10, as the anti–IL-10 used
consisted of an Ab mixture that had a profound effect on
IL-10 production by CD41 T cells at both the protein and
mRNA level (our unpublished observations). A more
likely possibility relates to the fact that IL-10 has downreg-
ulatory effects on TNF-a secretion (43–45), and that anti–
IL-10 administration was associated with increased TNF-a
production mainly by LP macrophages. Thus, it is possible
that intranasal pCMV-TGF-b plasmid administration com-
pletely prevented induction of TNBS colitis even in the
presence of anti–IL-10, because in this situation a large
number of macrophages capable of producing TNF-a and
mediating disease had not yet accumulated, whereas in es-
tablished colitis a large number of macrophages had accu-
mulated whose secretion of TNF-a was not immediately
suppressed in the presence of anti–IL-10.
The results obtained here, in parallel with previous stud-
ies of intranasal TGF-b DNA delivery, indicate that such
delivery ameliorates T cell–mediated inflammation whether
the latter is mediated by viral infection or, in this case, by
an antigen or antigens in the mucosal milieu (19). For these
observations to translate into therapy for human inflamma-
tion, much more must be known about the persistence of
the DNA in tissues and its possible harmful effects. In these
studies, we showed using RT-PCR with TGF-b1–specific
primers that mRNA arising from plasmid TGF-b1–encod-
ing DNA could be detected in tissues for 2 wk, as in previ-
ous reports, but was not detected after this time. As for pos-
sible harmful effects of DNA expressing TGF-b, in earlier
studies it was shown that intratracheal administration of
TGF-b1 (in an active form) via an adenovirus vector led to
severe lung fibrosis in a rat model (46). In addition, it was51 Kitani et al.
shown that transgenic mice carrying an active TGF-b1
DNA under the control of an albumin promotor expressed
TGF-b in hepatocytes and developed hepatic and renal fi-
brosis as well as atrophy of the pancreas and testis (47, 48).
In contrast, in our studies, careful histologic follow-up of
multiple tissues disclosed neither macroscopic nor micro-
scopic signs of fibrosis. The reason for this discrepancy from
previous studies is not yet known. However, it may relate
to the difference in the TGF-b1 DNA delivery system, and
thus the duration of TGF-b1 secretion.
Finally, the possibly unique characteristics of intranasal
delivery of plasmid as used here deserve comment. In pre-
vious reports, plasmid DNA encoding native TGF-b or ad-
enovirus encoding IL-4 were intraperitoneally adminis-
tered to rats with TNBS colitis, and plasmid DNA
encoding native TGF-b was administered by an intramus-
cular route to rats with streptococcal cell wall–induced ar-
thritis (49–51). Although these plasmid preparations had
therapeutic effects, they required multiple administration of
plasmid. In contrast, the intranasal gene delivery in this
study required only a single plasmid administration and was
noninvasive. These differences may relate to recent data
showing that nasal administration of antigen is a highly ef-
fective method of inducing oral tolerance, possibly because
of the presence of cells in nodes draining nasal passages that
readily populate mucosal tissues (52).
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